摘要
弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)多见于老年人,但老年患者通常治疗效果不佳,化疗不良反应较多,且个体差异较大,目前尚无最佳治疗方案,总体预后较差。R-CHOP方案(利妥昔单抗+环磷酰胺+长春新碱+多柔比星+泼尼松)为DLBCL的一线标准治疗方案,但部分老年患者难以耐受。针对老年患者,已探索出多种治疗方案,包括标准方案减量使用,标准方案联合某些新型药物,以及使用新的药物组合等,均取得了不同程度的成功。面对更多的治疗选择,根据患者年龄、一般体能状态、合并症和疾病病理特征等情况进行个体化治疗,早期选择合适的治疗方案,旨在提高患者疾病缓解率并减少复发,从而改善患者的预后。
Diffuse large B-cell lymphoma(DLBCL)is more common in the elderly,who often exhibit a poor treatment response,more adverse reactions to chemotherapy,and significant inter-individual differences.There is currently no optimal treatment regimen,and the overall prognosis for elderly patients with DLBCL is poor.The R-CHOP regimen(consisting of rituximab,cyclophosphamide,vincristine,doxorubicin,and prednisone)is the standard first-line therapy for DLBCL;however,some elderly patients find it difficult to tolerate.Various treatment plans to date have been explored for this specific group,including reducing R-CHOP use,combining R-CHOP with novel drugs,or utilizing new drug combinations.These approaches have achieved varying degrees of success.As the number of treatment options increases,individualized therapy is chosen according to patient age,general physical condition,and comorbidities as well as pathological characteristics of the disease.The key to improving prognosis lies in the early selection of an appropriate treatment plan to enhance remission and reduce recurrence rates.
作者
翁婉轩
高陆(综述)
任明强(审校)
Wanxuan Weng;Lu Gao;Mingqiang Ren(Department of Hematology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2023年第21期1119-1123,共5页
Chinese Journal of Clinical Oncology
基金
贵州省卫健委联合基金项目(编号:gzwkj2022-069)资助。
关键词
老年患者
弥漫性大B细胞淋巴瘤
治疗
新型药物
elderly patients
diffuse large B-cell lymphoma(DLBCL)
therapy
novel drugs
作者简介
翁婉轩,专业方向为血液病的诊断和治疗。E-mail:1458534624@qq.com;通信作者:任明强,844198637@qq.com。
